Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Pharmacology of Intravascular Radiocontrast Media

The Pharmacology of Intravascular Radiocontrast Media C metrizamide HO HO r CH,CO(CH,)N �� �"' * � I NH I NHCOCH, I CH,CO *� I iohexol H I CONC ICHOHCH'OH �H,::;: N CONHCH,CHOHCH,OH iopamidol CHOH I CHIOH 1 CH' HCO� * o I .... CH,OH CONHCH .... CH,OH I iotrol T OH H CONHCH;:,. ..... CH,OOHH CH, �HIOH �H20H CHOH CHOH CONHCH CHZOH CONHCH CH,OH i 0 HOHC I*N-CO-tHz-CO-N*CONHtH 0 CH,OH HtHNOC HOH,C I CH, CH, I CHOH HOH C I' I I I ..... I I I..... I I I CH,OH Figure 1 The structure of six different molecules currently in use in Europe or the United States illustrates the four classes of media available. All of the intravascular contrast media are derived from tri-iodinated benzoic acid precursors. dimer" in which two of the "monomer" molecules have been linked to form a monovalent anion while iotrol is a nonionic "dimer." lohexol, ioxaglate, and iopamidol contrast media are available for intravascular use in Europe and their approvals are currently pending in the United States. Intravascular injections of iohexol, iopamidol, and ioxaglate have been shown in numerous animal and RADIOCONTRAST MEDIA clinical studies to be less toxic than the currently used anion "monomers" (11-13). Metrizamide is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Pharmacology and Toxicology Annual Reviews

The Pharmacology of Intravascular Radiocontrast Media

Download PDF
18 pages

Loading next page...
 
/lp/annual-reviews/the-pharmacology-of-intravascular-radiocontrast-media-bh6Mcg0G4x
Publisher
Annual Reviews
Copyright
Copyright 1986 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0362-1642
eISSN
1545-4304
DOI
10.1146/annurev.pa.26.040186.001043
pmid
3521454
Publisher site
See Article on Publisher Site

Abstract

C metrizamide HO HO r CH,CO(CH,)N �� �"' * � I NH I NHCOCH, I CH,CO *� I iohexol H I CONC ICHOHCH'OH �H,::;: N CONHCH,CHOHCH,OH iopamidol CHOH I CHIOH 1 CH' HCO� * o I .... CH,OH CONHCH .... CH,OH I iotrol T OH H CONHCH;:,. ..... CH,OOHH CH, �HIOH �H20H CHOH CHOH CONHCH CHZOH CONHCH CH,OH i 0 HOHC I*N-CO-tHz-CO-N*CONHtH 0 CH,OH HtHNOC HOH,C I CH, CH, I CHOH HOH C I' I I I ..... I I I..... I I I CH,OH Figure 1 The structure of six different molecules currently in use in Europe or the United States illustrates the four classes of media available. All of the intravascular contrast media are derived from tri-iodinated benzoic acid precursors. dimer" in which two of the "monomer" molecules have been linked to form a monovalent anion while iotrol is a nonionic "dimer." lohexol, ioxaglate, and iopamidol contrast media are available for intravascular use in Europe and their approvals are currently pending in the United States. Intravascular injections of iohexol, iopamidol, and ioxaglate have been shown in numerous animal and RADIOCONTRAST MEDIA clinical studies to be less toxic than the currently used anion "monomers" (11-13). Metrizamide is

Journal

Annual Review of Pharmacology and Toxicology – Annual Reviews

Published: Apr 1, 1986

There are no references for this article.